Product
navicixizumab+paclitaxel
1 clinical trial
4 indications
Indication
Colorectal CancerIndication
Triple-Negative Breast CancerIndication
Stomach CancerIndication
Ovarian CancerClinical trial
A Phase 2, Multicenter, Open-Label Basket Study of Navicixizumab Monotherapy or in Combination With Paclitaxel or Irinotecan in Patients With Select Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-04-15